Alain P Algazi

List of Publications by Year
in descending order

61	15,932	87886 38	133244 59
papers	citations	h-index	g-index

63	63	63	21918
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Safety and Tumor Responses with Lambrolizumab (Antiâ€“PD-1) in Melanoma. New England Journal of Medicine, 2013, 369, 134-144.	27.0	3,128
2	Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations. New England Journal of Medicine, 2012, 367, 1694-1703.	27.0	2,445
3	Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet, The, 2019, 393, 156-167.	13.7	1,153
4	Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. New England Journal of Medicine, 2018, 379, 722-730.	27.0	983
5	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA - Journal of the American Medical Association, 2016, 315, 1600.	7.4	857
6	Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2012, 13, 1087-1095.	10.7	841
7	Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-Î³ and IL-12. Immunity, 2018, 49, 1148-1161.e7.	14.3	639
8	Tumor immune profiling predicts response to antiâ€“PD-1 therapy in human melanoma. Journal of Clinical Investigation, 2016, 126, 3447-3452.	8.2	439
9	The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nature Genetics, 2015, 47, 250-256.	21.4	434
10	Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Cancer Immunology Research, 2017, 5, 417-424.	3.4	400
11	Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. JAMA Dermatology, 2015, 151, 1206.	4.1	385
12	Intermodal selective attention. II. Effects of attentional load on processing of auditory and visual stimuli in central space. Electroencephalography and Clinical Neurophysiology, 1992, 82, 356-368.	0.3	313
13	Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction. Cancer Cell, 2015, 27, 240-256.	16.8	299
14	Clinical outcomes in metastatic uveal melanoma treated with PDâ€1 and PDâ€L1 antibodies. Cancer, 2016, 122, 3344-3353.	4.1	288
15	High response rate to PD-1 blockade in desmoplastic melanomas. Nature, 2018, 553, 347-350.	27.8	269
16	Overall Survival and Durable Responses in Patients With BRAF V600â€“Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. Journal of Clinical Oncology, 2016, 34, 871-878.	1.6	266
17	The efficacy of antiâ€PDâ€1 agents in acral and mucosal melanoma. Cancer, 2016, 122, 3354-3362.	4.1	236
18	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 643-654.	10.7	224

#	Article	IF	Citations
19	Intermodal selective attention. I. Effects on event-related potentials to lateralized auditory and visual stimuli. Electroencephalography and Clinical Neurophysiology, 1992, 82, 341-355.	0.3	212
20	Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 450-473.	4.9	203
21	Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAF^{V600}-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor. Journal of Clinical Oncology, 2014, 32, 3697-3704.	1.6	173
22	Processing of auditory stimuli during auditory and visual attention as revealed by event-related potentials. Psychophysiology, 1994, 31, 469-479.	2.4	154
23	Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 1083-1088.	1.3	145
24	Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncology, The, 2021, 22, 1692-1704.	10.7	129
25	Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma.. Journal of Clinical Oncology, 2015, 33, 3003-3003.	1.6	120
26	Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. British Journal of Cancer, 2017, 116, 1141-1147.	6.4	112
27	Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma. Clinical Cancer Research, 2020, 26, 2827-2837.	7.0	86
28	Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy. Cancer Cell, 2021, 39, 1375-1387.e6.	16.8	78
29	NCCN Guidelines Insights: Melanoma, Version 3.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 945-958.	4.9	76
30	Melanoma immunotherapy. Cancer Biology and Therapy, 2014, 15, 665-674.	3.4	73
31	Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Nature Medicine, 2020, 26, 1564-1568.	30.7	71
32	A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer. Clinical Cancer Research, 2017, 23, 1910-1919.	7.0	66
33	Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). Neuro-Oncology, 2021, 23, 1961-1973.	1.2	66
34	Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses. Cancer Immunology Research, 2020, 8, 246-254.	3.4	61
35	Dual MEK/AKT inhibition with trametinib and <scp>GSK</scp>2141795 does not yield clinical benefit in metastatic <scp>NRAS</scp>â€mutant and wildâ€type melanoma. Pigment Cell and Melanoma Research, 2018, 31, 110-114.	3.3	55
36	PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. Nature Communications, 2020, 11, 6262.	12.8	50

#	Article	IF	Citations
37	Brain potential signs of feature processing during auditory selective attention. NeuroReport, 1991, 2, 189-192.	1.2	48
38	Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 702	2.0	42
39	Durable treatment of ameloblastoma with single agent BRAFi Re: Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma. Journal of the National Cancer Institute, 2017, 109, .	6.3	42
40	Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Management and Research, 2010, 2, 197.	1.9	38
41	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 655-664.	10.7	37
42	Biology and Treatment of Primary Central Nervous System Lymphoma. Neurotherapeutics, 2009, 6, 587-597.	4.4	35
43	Treatment modality impact on quality of life for human papillomavirusâ€“associated oropharynx cancer. Laryngoscope, 2020, 130, E48-E56.	2.0	30
44	A watershed year for improvements in treatment?. Nature Reviews Clinical Oncology, 2017, 14, 76-78.	27.6	20
45	A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600^{E/K} mutant advanced melanoma. Pigment Cell and Melanoma Research, 2019, 32, 603-606.	3.3	18
46	Ultraviolet lightâ€related DNA damage mutation signature distinguishes cutaneous from mucosal or other origin for head and neck squamous cell carcinoma of unknown primary site. Head and Neck, 2019, 41, E82-E85.	2.0	17
47	Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-NaÃ¯ve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial. Clinical Cancer Research, 2022, 28, 1157-1166.	7.0	16
48	Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study. Clinical Cancer Research, 2022, 28, 903-914.	7.0	14
49	Intratumoral and Combination Therapy in Melanoma and Other Skin Cancers. American Journal of Clinical Dermatology, 2019, 20, 781-796.	6.7	11
50	Intratumoral Electroporation of Plasmid Encoded IL12 and Membrane-Anchored Anti-CD3 Increases Systemic Tumor Immunity. Molecular Cancer Research, 2022, 20, 983-995.	3.4	8
51	Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma. Annals of Surgical Oncology, 2020, 27, 4122-4130.	1.5	7
52	SWOG S1221: A phase 1 dose escalation study co-targeting MAPK-dependent and MAPK-independent BRAF inhibitor resistance in BRAF mutant advanced solid tumors with dabrafenib, trametinib, and GSK2141795 (ClinicalTrials.gov NCT01902173).. Journal of Clinical Oncology, 2017, 35, 2578-2578.	1.6	5
53	Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity. Molecular Therapy - Oncolytics, 2022, 25, 174-188.	4.4	5
54	Relationship between liver metastases and PD-1 blockade in melanoma.. Journal of Clinical Oncology, 2017, 35, 3072-3072.	1.6	3

#	Article	IF	Citations
55	Immune monitoring outcomes of patients with stage III/IV melanoma treated with a combination of pembrolizumab and intratumoral plasmid interleukin 12 (pIL-12).. Journal of Clinical Oncology, 2017, 35, 78-78.	1.6	3
56	NRAS-Mutant Melanoma: Response to Chemotherapy. Archives of Dermatology, 2011, 147, 626.	1.4	1
57	Sexual activity and function in male cancer patients receiving targeted an immune therapies.. Journal of Clinical Oncology, 2017, 35, e21594-e21594.	1.6	1
58	New horizons in melanoma treatment: targeting molecular pathways. Ochsner Journal, 2010, 10, 93-8.	1.1	1
59	Are PD-1 antibodies safe for use in metastatic uveal melanoma?. Melanoma Management, 2017, 4, 79-82.	0.5	0
60	Analysis of mutational burden and adaptive immune response in desmoplastic melanomas treated with PD-1/L1 inhibitors.. Journal of Clinical Oncology, 2017, 35, 9558-9558.	1.6	0
61	Patient attitudes toward oncofertility care in male cancer patients receiving targeted and immune therapies.. Journal of Clinical Oncology, 2017, 35, e21593-e21593.	1.6	0